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Serotonin 2C receptors (5-HT2CRs) are implicated in the pathomechanism and treatment
of anxiety and depression. Recently, as a new biomarker of depression, alterations in the
gamma power of the electroencephalogram (EEG) have been suggested. Chronic
treatment with the selective serotonin reuptake inhibitor (SSRI) antidepressant
escitalopram has been shown to cause sleep-wake stage-dependent alterations in
gamma power. However, despite the antidepressant potency of 5-HT2CR-antagonists,
there is no data available regarding the effects of selective 5-HT2CR-antagonists on
gamma activity. Therefore, we investigate the acute effect of the 5-HT2CR-antagonist SB-
242084 on gamma power in different vigilance stages when given in monotherapy, or in
combination with chronic escitalopram treatment. We administered SB-242084 (1 mg/kg,
intraperitoneally) or vehicle to EEG-equipped rats after a 21-day-long pretreatment with
escitalopram (10 mg/kg/day, via osmotic minipumps) or vehicle. Frontoparietal EEG,
electromyogram, and motor activity were recorded during the ﬁrst 3 h of passive phase,
after the administration of SB-242084. Quantitative EEG analysis revealed that acute SB-
242084 increased gamma power (30–60 Hz) in light and deep slow-wave sleep, and
passive wakefulness. However, in active wakefulness, rapid eye movement sleep, and
intermediate stage, no change was observed in gamma power. The proﬁle of the effect of
SB-242084 on gamma power was similar to that produced by chronic escitalopram.
Moreover, SB-242084 did not alter chronic escitalopram-induced effects on gamma. In
conclusion, the similarity in the effect of the 5-HT2CR-antagonist and chronic SSRI on
gamma power provides further evidence for the therapeutic potential of 5-HT2CR-
antagonists in the treatment of depression and/or anxiety.
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Serotonin (5-hydroxytryptamine, 5-HT) 2C receptors (5-
HT2CRs) are widely distributed in the brain, and mediate
regulatory effects of 5-HT on anxiety, sleep, hormonal
secretion, feeding behavior, locomotor activity, as well as
learning and memory processes (Bagdy, 1998; Chagraoui et al.,
2016). 5-HT2CR dysfunction has been implicated in pathological
conditions, like anxiety and depression (Chagraoui et al., 2016;
Di Giovanni and De Deurwaerdere, 2016). On the other hand,
numerous antidepressants, anxiolytics, and antipsychotics have
afﬁnities to the 5-HT2CRs, that may be involved in the
therapeutic effects of these drugs (Bagdy et al., 2001; Chagraoui
et al., 2016; Di Giovanni and De Deurwaerdere, 2016). Thus, 5-
HT2CR is a promising pharmacological target in the treatment of
several neuropsychiatric disorders (Chagraoui et al., 2016; Di
Giovanni and De Deurwaerdere, 2016).
Stimulation of 5-HT2CRs has been described to produce
anxiety, and in turn, subtype-selective 5-HT2CR-antagonists
like SB-242084 exerted marked anxiolytic effects (Dekeyne
et al., 2000; Bagdy et al., 2001; Kantor et al., 2005). The
selective 5-HT2CR-antagonists RS-102221 and SB-242084
produced fast-onset antidepressant-like effects in mice (Opal
et al., 2014). Also, 5-HT2CR-antagonism potentiated the
anxiolytic and antidepressant effects of ﬂuoxetine, a selective
serotonin reuptake inhibitor (SSRI), moreover, reduced motor
side effects in mice (Demireva et al., 2018). Importantly, the
interaction of 5-HT and dopamine (DA) systems has been
suggested to contribute to these effects (De Deurwaerdere and
Di Giovanni, 2017).
Various parameters on the electroencephalogram (EEG)
during both wakefulness and sleep have been described to
provide biomarkers of depression and of individualized
antidepressant therapy (Steiger and Kimura, 2010). Gamma
oscillations are relatively high-frequency (>30 Hz) components
of the EEG, that provide important clues about neuronal
population dynamics (Buzsaki and Wang, 2012). Gamma
oscillations have been associated with sensory and cognitive
functions, as well as neural plasticity and memory in animals
and humans (Cardin, 2016). On the other hand, abnormal
gamma activity has been implicated in several psychiatric
conditions (Cardin, 2016). Based on the growing body of
evidence suggesting the involvement of gamma in the
pathomechanism of depression, alterations in gamma
oscillations have recently been proposed as a novel biomarker
(or endophenotype) for major depression and even for the
follow-up of the antidepressant therapies (Fitzgerald and
Watson, 2018). Several antidepressants have been shown to
alter gamma activity (Fitzgerald and Watson, 2018). For
instance, the SSRI escitalopram has been found to decrease
gamma power during rapid eye movement sleep (REMS) in
acute treatment, while chronic escitalopram increased gamma
power during slow-wave sleep stages (Papp et al., 2018).
However, it is still an open question whether the drug-induced
alterations of gamma activity in different vigilance stages are
indicators or causative mediators of therapeutic action, or signs
of side effects (Fitzgerald and Watson, 2018).Frontiers in Pharmacology | www.frontiersin.org 2According to our knowledge, there is a gap in the literature
regarding the effects of selective 5-HT2CR-antagonists on gamma
oscillations in humans and in rodents. So, here we investigate
how gamma power (30–60 Hz) is changing in different vigilance
stages (i) by acute administration of the highly selective 5-
HT2CR-antagonist SB-242084, (ii) by chronic administration of
the extensively used SSRI escitalopram, (iii) and by
their combination.METHODS
Male Wistar rats, purchased from the local Animal Facility
(Semmelweis University, Budapest, Hungary), were used in the
experiments. The animals were kept under controlled
environmental conditions (21 ± 1°C, 12/12 h light-dark cycle
with lights on at 10 AM), and were provided free access to
standard rodent chow and tap water. All housing conditions and
animal experiments were performed in accordance with the EU
Directive 2010/63/EU and the National Institutes of Health
“Principles of Laboratory Animal Care” (NIH Publications No.
85–23, revised 1985), as well as speciﬁc national laws (the
Hungarian Governmental Regulations on animal studies 40/
2013). The experiments were approved by the National
Scientiﬁc Ethical Committee on Animal Experimentation. All
efforts were made to minimize pain and discomfort of
the animals.
Electroencephalographic (EEG) and electromyographic
(EMG) electrodes were implanted under 2% halothane
anesthesia, as described earlier (Jakus et al., 2003). The rats
weighed 250–280 g at surgery. For EEG, stainless steel screw
electrodes were inserted epidurally over the left frontal cortex (L:
2.0 mm, A: 2.0 mm to bregma), left parietal cortex (L: 2.0 mm, A:
2:0 mm to lambda), and over the cerebellum as a ground
electrode. For EMG, a pair of EMG electrodes (stainless steel
spring electrodes covered by silicon rubber, Plastics One Inc.,
Roanoke, VA, USA) was placed into the neck musculature. After
recovery (7 days), the rats were attached to the EEG system by a
recording cable and an electric swivel ﬁxed above the cages. The
animals remained connected throughout the whole study.
For chronic pretreatment, the rats received 10 mg/kg/day
escitalopram-oxalate solution (ESC Gedeon Richter Plc.,
Hungary, dissolved in a solution of 0.3 N HCl in distilled
water) or vehicle (VEH; solution of 0.3 N HCl in distilled
water) via osmotic minipump (2ML4, ALZET, 2.5 ml/h,
DURECT Corporation, USA) for 21 days. On the 21st day, the
rats received intraperitoneal injections of 1 mg/kg SB-242084
[SB; Tocris, UK, dissolved in a solution of 10% (2-
hydroxypropyl)-b-cyclodextrin] or vehicle [veh; solution of
10% (2-hydroxypropyl)-b-cyclodextrin] in a volume of 1 ml/kg
body weight. The rats were randomly divided into four groups as
follows: VEH+veh (n = 6), VEH+SB (n = 6), ESC+veh (n = 6),
and ESC+SB (n = 6).
EEG, EMG, and motor activity were recorded for at least 3 h
after the injections, starting at light onset. The signals were
ampliﬁed by analogue ﬁlters (Coulburn Lablinc System, USA;
ﬁltering below 0.50 Hz and above 100 Hz at 6 dB/octave) andJanuary 2020 | Volume 10 | Article 1636
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Canopus, Japan) with a sampling rate of 128 Hz. Data were
stored on a computer for further processing.
The polygraphic recordings were scored using the automated
scoring function of Sleep Sign for Animal (Kissei Comtec
America Inc., USA) software for 4-s epochs, followed by visual
supervision. Six vigilance stages were distinguished based on
conventional criteria (Kantor et al., 2004) as follows (see
Supplementary Figure 1 for representative traces). In active
wakefulness (AW), the EEG is characterized by low-amplitude
activity at beta (14–29 Hz) and alpha (10–13 Hz) frequencies, in
addition to intense EMG and motor activity. In passive
wakefulness (PW), the EEG pattern is similar to AW,
accompanied by a relatively high EMG activity and minimal or
no motor activity. In light slow-wave sleep (SWS-1), the EEG is
characterized by high-amplitude slow cortical waves (0.5–4 Hz)
interrupted by spindles (6–15 Hz), accompanied by reduced
EMG activity and no motor activity. In deep slow-wave sleep
(SWS-2), the EEG is dominated by continuous high-amplitude
slow cortical waves with reduced EMG and no motor activity. In
intermediate stage of sleep (IS), that occurs mostly before or after
REMS, the EEG is characterized by an association of high-
amplitude spindles and theta (5–9 Hz) waves. In REMS, the
EEG is dominated by low-amplitude and high-frequency activity
with regular theta waves, in addition to the silent EMG and
motor activity with occasional muscle contraction (twitching).
Epochs that were contaminated with artefacts or contained
transition between vigilance stages were discarded.
The quantitative EEG (qEEG) analysis was computed for
consecutive 4-s epochs in the frequency range of 0.5–60 Hz by
means of fast Fourier transformation (Hanning window,
frequency resolution of 0.25 Hz). Adjacent 0.25-Hz bins were
summed into 1-Hz bins which are marked by their upper limits.
The power values of epochs in AW, PW, SWS-1, SWS-2, IS, and
REMS were separately averaged in the summarized 3 h, or in the
ﬁrst, second, and third h respectively, after treatments to obtain
power density values for these sleep-wake stages. In this report,
we focused on the 30–60 Hz frequency range of the EEG power
spectra. Data within 49–51 Hz were excluded from the analysis
to avoid contamination of the 50 Hz interference noise from the
electrical network. All data were log-transformed before analysis.
For power spectral analysis, comparisons among groups were
performed by two-way ANOVA on repeated measures with two
main factors: treatment (non-repeated) and gamma frequency
bins (repeated), followed by Bonferroni post hoc test. To
investigate treatment effects in each h, summarized 30–60 Hz
power data (excluding those of 49–51 Hz) were analyzed using
one-way ANOVA, regarding AW, PW, SWS-1, SWS-2, IS, and
REMS respectively. Following detection of a signiﬁcant main
treatment effect, post hoc Newman–Keuls tests were conducted.
Statistical signiﬁcance was accepted when p < 0.05.
In our experimental design, control rats (VEH+veh) were
exposed to the same procedures as drug-treated ones. Thus, the
comparison of the drug-treated groups and the control group is
aimed at minimizing the distress caused by the injections and the
presence of the minipumps, allowing to study the effects of theFrontiers in Pharmacology | www.frontiersin.org 3drugs. For spectral graphs, in favor of better visibility (as EEG
power data follow a decreasing tendency with increasing
frequencies), we normalized power values of drug-treated rats
to the mean power spectral values of the control ones (VEH+veh
group), thus showing relative data. Absolute data are presented
on the bar graphs, as summarized power values. Data are
expressed as mean ± SEM of six animals per group.RESULTS
Effects of the drugs (acute SB-242084, chronic escitalopram, and
their combination) on the qEEG in the 30–60 Hz gamma range
were evaluated separately for the six vigilance stages by averaging
the power data in the ﬁrst 3 h of the passive phase (Figure 1).
The analysis revealed that all of the drugs caused vigilance stage-
dependent alterations in this frequency range, with a tendency
for elevation in each stage, compared to the VEH+veh group.
During AW, ANOVA results showed no signiﬁcant alterations
(treatment effect: F3,20 = 1.917, p = 0.1594; treatment x frequency
interaction: F81,540 = 1.218, p = 0.1081; Figure 1A). However,
during PW, a moderately elevated power line was seen in the SB
groups, and at the higher frequencies also in the ESC+veh group
(treatment effect: F3,20 = 2.217, p = 0.1176; signiﬁcant treatment x
frequency interaction: F81,540 = 2.519, p < 0.001; Figure 1B).
The most prominent effects were observed during slow-wave
sleep stages, where the acute SB-242084, the chronic
escitalopram, and also the combined treatment caused a power
elevation. This was supported by signiﬁcant ANOVA results in
SWS-1 (treatment effect: F3,20 = 3.692, p = 0.0290; signiﬁcant
treatment x frequency interaction: F81,540 = 2.693, p < 0.001;
Figure 1C), and in SWS-2 (signiﬁcant treatment effect: F3,20 =
4.787, p = 0.0113; signiﬁcant treatment x frequency interaction:
F81,540 = 1.911, p < 0.001; Figure 1D).
The gamma power increase was not signiﬁcant during IS
(treatment effect: F3,20 = 2.349, p = 0.1031, treatment x frequency
interaction: F81,540 = 1.241, p = 0.0878; Figure 1E). Finally, during
REMS, neither the acute SB-242084 nor the chronic escitalopram
affected the EEG power in this frequency range (treatment effect:
F3,19 = 2.515, p = 0.0891; treatment x frequency interaction:
F81,513 = 1.226, p = 0.1014; Figure 1F). We note that the data of
only n = 5 animals were used in the ESC+SB group, as one animal
did not spend any time in REMS in this time interval.
For signiﬁcant Bonferroni post hoc differences following
the signiﬁcant two-way ANOVA results described above, see
Figure 1 for each vigilance stage. No signiﬁcant post hoc
differences were seen in any of the stages regarding
comparisons of VEH+SB vs. ESC+veh, VEH+SB vs. ESC+SB,
and ESC+veh vs. ESC+SB, respectively.
The sleep-wake stage-dependent effects of the drugs on total
gamma power were analyzed hourly. One-way ANOVA revealed
that although in the ﬁrst h of SWS-1, the treatment effect was not
signiﬁcant yet (F3,20 = 2.544, p = 0.0851), in the second (F3,20 =
3.331, p = 0.0403) and third h (F3,20 = 4.607, p = 0.0131) the
power elevations were signiﬁcant. In SWS-2, ANOVA showed
signiﬁcant treatment effects in each h (F3,18 = 4.062, p = 0.0228;January 2020 | Volume 10 | Article 1636
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Also, a signiﬁcant effect was found in the second h of IS (F3,20 =
3.452, p = 0.0360), but not in the ﬁrst or third h. Finally, no
signiﬁcant treatment effect was found in these hours in AW, PW,
and REMS. For signiﬁcant post hoc results, see Figure 2 for each
vigilance stage.DISCUSSION
This is the ﬁrst study investigating the acute effects of the selective
5-HT2CR-antagonist SB-242084 on the gamma frequency band of
the EEG spectra in different vigilance stages. In addition, it was
tested with or without chronic SSRI pretreatment. Here we report
an enhanced gamma band power during SWS-2, SWS-1, and PW
following administration of acute SB-242084, (1 mg/kg, ip.), in
rats. Our ﬁndings about the additional 21-day-long pretreatmentFrontiers in Pharmacology | www.frontiersin.org 4with escitalopram (10 mg/kg/day, osmotic minipumps)
demonstrate that SB-242084 did not modify further the gamma
power altered by the chronic antidepressant treatment. Moreover,
the acute effects of SB-242084 and the chronic effects of
escitalopram on gamma power seemed very similar in most
vigilance stages. However, the effects of the combination of
these two treatments were not considered as additive.
Brain functions related to gamma activity were discussed in
the introduction section. Gamma oscillations have been
described in multiple areas of the brain, such as neocortex,
entorhinal cortex, hippocampus, thalamus, amygdala, olfactory
bulb, and striatum. Their generation is tied to perisomatic
inhibition; most of all, the activity of parvalbumin-positive
interneurons via gamma-aminobutyric acid (GABA)A synapses
(Buzsaki and Wang, 2012). Gamma oscillations are thought to
play an important role in depression, which is supported by both
human and animal ﬁndings. Namely, gamma abnormalities wereFIGURE 1 | EEG power changes in the gamma frequency range (30–60 Hz) following the administration of acute SB-242084 (VEH+SB), chronic escitalopram
(ESC+veh), and their combination (ESC+SB) in the ﬁrst 3 h of the passive phase. Power spectra are shown in the following six vigilance stages: (A) active (AW) and
(B) passive wakefulness (PW), (C) light (SWS-1) and (D) deep slow-wave sleep (SWS-2), (E) intermediate stage (IS), and (F) rapid eye movement sleep (REMS).
EEG power data are presented as mean ± SEM, relative to the VEH+veh control group (n = 6 animals per group). *Signiﬁcant post hoc results compared to control,
p < 0.05.January 2020 | Volume 10 | Article 1636
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depression, where changes in gamma were associated with
therapeutic recovery (Khalid et al., 2016; Noda et al., 2017;
Fitzgerald and Watson, 2018).
Various pharmacological (targeting serotonin, noradrenaline,
dopamine, and glutamate systems) and non-pharmacological
treatments of depression have been shown to alter gamma
activity (Fitzgerald and Watson, 2018). For instance,
escitalopram, the extensively used SSRI antidepressant, acting
on the serotonergic system, has been shown to reduce gamma
power during REMS by acute treatment, while its chronic
administration increased gamma power in slow-wave sleepFrontiers in Pharmacology | www.frontiersin.org 5stages, in rats (Papp et al., 2018). Importantly, antidepressants
acting on the noradrenergic system, such as reboxetine and
desipramine, increased gamma (as well as theta) power in the
septo-hippocampal system following acute treatment, whereas
the SSRI ﬂuvoxamine failed to produce such an effect in the same
study (Hajos et al., 2003a). The putative next-generation
antidepressants, such as ketamine and its metabolite (2R,6R)-
hydroxynorketamine have been shown to prominently boost
gamma power when applied in antidepressant-relevant doses.
These effects and also their antidepressants-like actions were
prevented by pretreatment with an a-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid receptor (AMPAR) inhibitorFIGURE 2 | Total EEG power in the gamma frequency range (30–60 Hz) following the administration of acute SB-242084 (VEH+SB), chronic escitalopram
(ESC+veh), and their combination (ESC+SB) in the ﬁrst, second, and third h of the passive phase, during (A) active (AW) and (B) passive wakefulness (PW),
(C) light (SWS-1) and (D) deep slow-wave sleep (SWS-2), (E) intermediate stage (IS), and (F) rapid eye movement sleep (REMS). Summarized EEG power
data are presented as mean ± SEM (of n = 6 animals per group). *Signiﬁcant post hoc results compared to the control group (VEH+veh), p < 0.05.January 2020 | Volume 10 | Article 1636
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proposed that gamma signaling may provide a biomarker of the
antidepressant effects of all classes of antidepressants, as,
according to their hypothesis, all classes of antidepressants
may have common ﬁnal effects on the limbic circuitry
(Fitzgerald and Watson, 2019).
In this study, we examined drugs acting on the 5-HT system,
namely, an antagonist of 5-HT2CR and an SSRI with the main
action of increasing the extracellular level of 5-HT by inhibiting
its synaptic reuptake via the 5-HT-transporter. A growing body
of evidence suggests that 5-HT2CR-antagonism might provide
beneﬁcial effects in the therapy of depression and anxiety,
although these effects of the selective 5-HT2CR-antagonists
have not been tested in clinical studies yet. Supporting the
relevance of combining 5-HT2CR-antagonists with SSRIs, the
acute co-administration of the selective 5-HT2CR-antagonists
SB-242084 or RS-102221 with the SSRI citalopram augmented
the citalopram-induced elevations of 5-HT levels in regions
implicated in the pathophysiology of depressive disorders, in a
microdialysis study in rats (Cremers et al., 2004). Pretreatment
with SB-242084 also reversed the acute citalopram-induced
enhancement of fear expression in rats (Burghardt et al., 2007).
Furthermore, a recent paper has shown that acute SB-242084
treatment after chronic (21 days) ﬂuoxetine treatment reduced
the anxiety- and depression-like behaviors, and ameliorated the
SSRI-induced side effects in mice (Demireva et al., 2018).
In the present study, 1 mg/kg SB-242084 dose was chosen,
based on former behavioral (Kennett et al., 1997; Martin et al.,
2002; Opal et al., 2014) and sleep and/or EEG (Popa et al., 2005;
Sorman et al., 2011; Bogathy et al., 2019) studies in rodents.
Importantly, Kantor et al. have demonstrated that although 0.3
and 1.0 mg/kg doses of the drug produced similar anxiolytic
effects, only the higher dose affected the sleep-wake architecture
prominently (wake-promoting effect with reduction of SWS-2),
in Sprague-Dawley rats (Kantor et al., 2005). A REMS-reducing
effect have been found at 1 mg/kg dose in Wistar rats, and theta
power elevations during AW and REMS have also been observed
following this treatment (Kostyalik et al., 2014).
The effect of the SB-242084 and escitalopram on gamma
activity was analyzed separately in vigilance stages, since brain
functions and associated oscillatory activity, and neurotransmitter
levels show characteristic differences between stages. The role of
gamma oscillations in functions linked to wakefulness such as
focused attention, cognition, and sensory processing is well
documented (Cardin, 2016), however, their functional
importance during sleep is less understood. During REMS, a role
of gamma (beyond theta) oscillations in memory consolidation has
been suggested (Montgomery et al., 2008). A recent paper has
proposed that increased gamma power in phasic REMS microstate
in certain areas is associated with emotional processing, in humans
(Simor et al., 2019). During non-REMS, gamma oscillations might
be associated with phasic increases of neural activity during slow
oscillations (Valderrama et al., 2012). A microelectrode-study in
monkeys and humans has further emphasized the role of gamma
(and beta) oscillations during non-REMS, namely, a high
oscillation coherence suggests a contribution a contribution ofFrontiers in Pharmacology | www.frontiersin.org 6gamma to memory consolidation to memory consolidation during
non-REMS (Quyen et al., 2016).
We found that a single dose of SB-242084 elevated gamma
power during SWS-2, SWS-1, and— to a lesser extent— PW, but
not during REMS, IS, and AW.
5-HT neurons ﬁre most actively during wakefulness, their
activity decreases during slow-wave sleep, and falls silent during
REMS. The 5-HT system has thus been considered a key
modulator of sleep-wake behavior (Monti, 2011) and brain
oscillations, although the cellular mechanisms and the
receptors involved in these processes are complex and poorly
understood (Puig and Gener, 2015). 5-HT per se has been found
to affect gamma activity in the rat prefrontal cortex through 5-
HT1ARs and 5-HT2ARs, but not 5-HT2CRs, resulting in an
overall decrease in amplitude in anesthetized rats (Puig et al.,
2010). Furthermore, there is a mounting evidence supporting the
importance of the DA system in synchronization of fast-spiking
interneurons, thus generating/regulating gamma oscillations
(Furth et al., 2013).
5-HT2CR is presumably the 5-HT receptor subtype with the
most widespread distribution in the brain. It has been described
on GABAergic interneurons in numerous regions, and is also
expressed by DA neurons. However, this receptor subtype is not
expressed by 5-HT and noradrenergic (NA) neurons. The role of
5-HT2CRs in the modulation of the monoaminergic, and
intriguingly, the DA systems has been underlined by several
preclinical studies (Di Giovanni and De Deurwaerdere, 2016; De
Deurwaerdere and Di Giovanni, 2017). Local stimulation of the
5-HT2CRs in speciﬁc brain areas produced anxiety in a region-
dependent manner, and in turn, subtype-selective 5-HT2CR-
antagonists like SB-242084 exerted marked anxiolytic actions
(Bagdy et al., 2001; Di Giovanni and De Deurwaerdere, 2016).
Several anxiolytics and antidepressants possess 5-HT2CR
antagonist properties, for example, numerous tricyclic
antidepressants , mianserin, mirtazapine, trazodone,
nefazodone, ﬂuoxetine, and agomelatine (Martin et al., 2014).
On the other hand, selective 5-HT2CR antagonists have been
suggested as putative fast-onset antidepressants based on
preclinical studies (Opal et al., 2014).
A few studies have been published regarding qualitative
(affecting sleep-wake architecture) and quantitative (affecting
power spectra, i.e. oscillations) sleep-wake effects of 5-HT2CR
antagonists, and SB-242084 particularly. Kantor et al. have
investigated the dose-dependent effects of SB-242084 on anxiety,
vigilance, and EEG spectra below 30 Hz in rats. They have found
increased theta power in wakefulness (that suggests a possible a
possible cognitive-enhancing effect, as theta activity is associated
with learning and memory processes) even at 0.1 mg/kg dose. In
contrast, the drug increased wake and suppressed SWS-2 in the
ﬁrst h of passive phase only at 1 mg/kg dose. Regarding delta,
alpha, or beta frequency bands during wakefulness, REMS, SWS-
1, or SWS-2, no signiﬁcant alteration has been reported in this
paper (Kantor et al., 2005). Kostyalik et al. have described that SB-
242084 elevated PW duration, and suppressed REMS which effect
was attenuated by chronic ESC pretreatment, in rats. Regarding
qEEG, they have found enhanced theta power during AW andJanuary 2020 | Volume 10 | Article 1636
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escitalopram pretreatment (Kostyalik et al., 2014). The theta-
enhancing effect of the 5-HT2CR-antagonist and thus the role of
5-HT2CR in the regulation of theta activity have been supported
by Hajos et al. (2003b).
The effects of escitalopram and other SSRIs on sleep-wake
architecture and EEG parameters in humans and rodents are
more extensively studied (Wilson and Argyropoulos, 2005; Vas
et al., 2013; Fitzgerald and Watson, 2019). Recently, we have
reported gamma power alterations following acute (reduction
during REMS) and chronic (elevation during SWS-1 and SWS-2)
administration to rats (Papp et al., 2018).
Interestingly, the acute effects of SB-242084 were similar to
those caused by chronic escitalopram, with other words, selective
antagonism on 5-HT2CR produced similar effects on gamma
activity as the chronic blockade of the 5-HT-transporter and
additional effects escitalopram exerts. In that case, we presume
that effects of 5-HT, namely, the desensitization of 5-HT1AR (and
possibly also 5-HT2AR) may account for the increase in gamma
power in those stages, as we have proposed in our previous paper
(Papp et al., 2018).
To explain our ﬁndings, we must take into consideration that
5-HT2CRs can modulate 5-HT, NA, and importantly, DA
neuronal activity (Di Giovanni and De Deurwaerdere, 2016).
Constitutive activity of the 5-HT2CRs has been reported to exert
inhibitory control on DA neuron activity, which was reversed by
systemic administration of 5-HT2CR antagonists. SB-242084 and
SB-206553 signiﬁcantly enhanced basal DA release in DA
innervated areas of the rat brain. However, the SB-242084
elicited DA release was small, and reached a maximum
compared with SB-206553 (De Deurwaerdere et al., 2004).
Interestingly, SSRIs have also been implicated in regulating
DAergic signaling (that might indicate a possible common
feature of the two investigated drugs), although the available
literature data are ambiguous. While acute escitalopram has been
reported to increase the ﬁring rate and bursting of neurons in the
ventral tegmental area (Schilstrom et al., 2011), another study
has demonstrated that a 2-week-long administration of
escitalopram decreased the ﬁring rate and bursting of these
neurons, in anesthetized rats (Dremencov et al., 2009).
The ﬁndings of this study should be interpreted in the context
of some limitations. SB-242084 was administered in one dose
only, and we did not test whether the gamma-enhancing effect of
the drug is dose-dependent. In addition, our analysis was limited
to a maximum of 60 Hz due to the Nyquist limit determined by
the nominal sampling rate, thus further work is required to
investigate faster gamma frequencies, as well as high-frequency
oscillations (HFO) and ripples.
Taken together, our ﬁndings show similar effects between
acute SB-242084 and chronic escitalopram on gamma activity,
which support preclinical (and indirect clinical) evidences that
acute or short-term treatment with 5-HT2CR-antagonists may
have antidepressant effects. Thus, our work might provide
further evidence that 5-HT2CR-antagonists may be beneﬁcial in
the treatment of depression and/or anxiety. Whether alterations
of gamma activity are markers of therapeutic drug action orFrontiers in Pharmacology | www.frontiersin.org 7mediators of therapeutic effect, remains an unresolved question
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